2:30 Roundtable Discussion: Discussing Unique PK/PD Properties of Degraders

Time: 10:15 am
day: Day 1 Track B morning


  • Given the notoriously low oral bioavailability of PROTACs, what is your strategy to achieve efficacious concentrations in vivo?
  • What is your view regarding PK/PD requirements for long-acting parenteral PROTACs?
  • Have you observed any loss of efficacy after repeat treatment and, if so, what could be the potential mechanisms?